MCM
TVRD

MAI Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

MAI Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45 Buy
14
+4
+40% +$16 ﹤0.01% 4881
2025
Q4 		$43 Hold
10
– – ﹤0.01% 4253
2025
Q3 		$390 Hold
10
– – ﹤0.01% 3651
2025
Q2 		$234 Hold
10
– – ﹤0.01% 3852
2025
Q1 		$153 Hold
10
– – ﹤0.01% 3339
2024
Q4 		$184 Buy
+10
New +$109 ﹤0.01% 3388

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

MAI Capital Management's TVRD Position: Q1 2026 in Review

MAI Capital Management increased its Tvardi Therapeutics (TVRD) stake by 40% in Q1 2026, buying an estimated $16 and bringing the position to 14 shares worth $45. The position accounts for ﹤0.01% of the portfolio, ranked #4881.

MAI Capital Management first reported a position in TVRD in Q4 2024 and has held it in 6 quarters since. The position peaked at $390 in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • MAI Capital Management held 14 shares of Tvardi Therapeutics worth $45 as of Q1 2026.
  • MAI Capital Management bought 4 Tvardi Therapeutics shares in Q1 2026, an estimated $16.
  • Tvardi Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4881 holding.
  • MAI Capital Management first reported a position in Tvardi Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's Tvardi Therapeutics position peaked at $390 in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.